https://www.selleckchem.com/products/lf3.html
Clinical success for omadacycline-treated patients at ECR were similar across ascending BMI groups (OMC 82.9%, 80.5%, 76.9%; MOX 88.6%, 80.7%, 76.9%). Outcomes by diabetes status were generally similar in omadacycline- and moxifloxacin-treated patients. Patients who had clinical success or clinical stability at ECR generally showed continued clinical success at PTE. Safety profiles for omadacycline and moxifloxacin were largely similar across BMI subgroups and by diabetes history. The omadacycline fixed-dosing strategy showed consistent saf
Like
Comment
Share
